Greg Elson

Greg is a product development leader with more than 25 years of experience in the BioPharma industry who joined Alentis in April 2019. He has with a strong track record of designing and executing development strategies for innovate biologics based on cutting edge technologies, whilst building and providing leadership to dedicate teams of SMEs and program heads.

Prior to this role, Greg was most recently VP Biologics CMC at Glenmark Pharmaceuticals. In this role he was responsible for cascading vision and strategy for the development and production for clinical development of a large pipeline of mAb, bispecific and biosimilar products to a department of highly-trained scientists and engineers.

Previously, Greg was CMC/Bioprocess Sciences Department Head, as well as having Product Discovery/Development responsibilities at NovImmune SA. Prior to that he was also a discovery scientist at the Pierre Fabre Immunology Research Centre and the Glaxo Institute Biomedical Research Institute. Greg is also the owner of GE Consulting, providing BioPharma product development solution to a portfolio of SME and startup ventures.

He holds a PhD in Molecular Biology, from the University of Manchester, UK.